---
title: "GYRE.US (GYRE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GYRE.US/news.md"
symbol: "GYRE.US"
name: "GYRE.US"
parent: "https://longbridge.com/en/quote/GYRE.US.md"
datetime: "2026-05-20T22:53:50.657Z"
locales:
  - [en](https://longbridge.com/en/quote/GYRE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GYRE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GYRE.US/news.md)
---

# GYRE.US (GYRE.US) — Related News

### [Gyre COO Ye Weiguo sells USD 59,833 Gyre Therapeutics shares](https://longbridge.com/en/news/287111332.md)
*2026-05-20T20:02:22.000Z*
> Gyre Therapeutics COO Weiguo Ye sold 9,320 shares at weighted-average prices of $6.62 and $6.37, reducing his stake to 7

### [Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027](https://longbridge.com/en/news/286472408.md)
*2026-05-14T21:33:01.000Z*
> Gyre Therapeutics will present preclinical data on CG923308 at a Shanghai conference, highlighting its potent anti-tumor

### [Gyre Therapeutics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 22.52 M](https://longbridge.com/en/news/285771934.md)
*2026-05-08T20:25:08.000Z*
### [Gyre Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 22.52 M](https://longbridge.com/en/news/285657745.md)
*2026-05-08T03:24:42.000Z*
### [Ying Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock](https://longbridge.com/en/news/285651439.md)
*2026-05-08T02:15:29.000Z*
> Ying Luo, CEO of Gyre Therapeutics (NASDAQ:GYRE), sold 10,136 shares at an average price of $8.04, totaling $81,493.44. 

### [Gyre Therapeutics (NASDAQ:GYRE)  Shares Down 11.4%  on Disappointing Earnings](https://longbridge.com/en/news/285589526.md)
*2026-05-07T16:54:33.000Z*
> Shares of Gyre Therapeutics (NASDAQ:GYRE) fell 11.4% to $7.1250 following disappointing earnings, missing EPS estimates 

### [](https://longbridge.com/en/news/285587487.md)
*2026-05-07T16:23:14.000Z*
> Gyre Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.

### [Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company | GYRE Stock News](https://longbridge.com/en/news/285074408.md)
*2026-05-04T04:47:00.000Z*
> Gyre Therapeutics has completed its acquisition of Cullgen in an all-stock deal valued at approximately $300 million, cr